Charles River Laboratories International, Inc.
CRL
주식 순위
#1447
Charles River Laboratories International, Inc. operates as a contract research... Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
주가
$315.50
시가총액
$15.20B
변동 (1일)
5.45%
변동 (1년)
71.34%
국가
US
거래 Charles River Laboratories International, Inc. (CRL)
카테고리
Healthcare
Charles River Laboratories International, Inc. (CRL)의 수익
Jun 2026 기준 수익 TTM: $-183.67M
Charles River Laboratories International, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-183.67M입니다. 2023년에 회사는 $581.28M의 수익을 올렸으며 이는 2022년의 수익 $622.99M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Charles River Laboratories International, Inc.의 수익 기록 (2000 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-183.67M | -297.25% |
| 2024 | $93.11M | -83.98% |
| 2023 | $581.28M | -6.69% |
| 2022 | $622.99M | 29.60% |
| 2021 | $480.71M | 7.51% |
| 2020 | $447.11M | 47.04% |
| 2019 | $304.08M | 7.95% |
| 2018 | $281.68M | -5.14% |
| 2017 | $296.96M | 33.21% |
| 2016 | $222.92M | 14.07% |
| 2015 | $195.43M | 10.04% |
| 2014 | $177.60M | 28.39% |
| 2013 | $138.33M | 6.61% |
| 2012 | $129.75M | -2.20% |
| 2011 | $132.66M | -139.71% |
| 2010 | $-334.08M | -324.06% |
| 2009 | $149.11M | -132.34% |
| 2008 | $-461.01M | -312.03% |
| 2007 | $217.42M | 23.14% |
| 2006 | $176.56M | 10.07% |
| 2005 | $160.41M | 5.17% |
| 2004 | $152.53M | 15.00% |
| 2003 | $132.63M | 15.93% |
| 2002 | $114.40M | 64.66% |
| 2001 | $69.48M | 170.20% |
| 2000 | $25.71M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $7.61B | -4,242.73% |
US
|
|
| $4.76B | -2,692.68% |
US
|
|
| $-252.70M | 37.58% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -1,002.70% |
US
|
